Decision: Favourable

Study Title:

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Prof Ray McDermott

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Mirati Therapeutics, Inc.

Scroll to Top